Title of article
Safe Administration of anti-PD-L1 Atezolizumab in aPatient with Metastatic Urothelial Cell Carcinoma andEnd-Stage Renal Disease on Dialysis
Author/Authors
Ficorella, Corrado Medical Oncology - St. Salvatore Hospital - L’Aquila, Italy , Parisi, Alessandro Medical Oncology - St. Salvatore Hospital - L’Aquila, Italy , Cortellini, Alessio Medical Oncology - St. Salvatore Hospital - L’Aquila, Italy , Cannita, Katia Medical Oncology - St. Salvatore Hospital - L’Aquila, Italy , Bersanelli, Melissa Medical Oncology - University Hospital of Parma- Parma, Italy
Pages
4
From page
1
To page
4
Abstract
Anti-PD-L1 (programmed cell death-ligand 1) agents, such as atezolizumab, have been approved for the treatment of differentadvanced cancers. However, no study enrolled end-stage renal disease (ESRD) patients, and to our knowledge, there are nosignificant published data about safety and efficacy of PD-L1 inhibitors in this population. Here, we report thefirst case of amale patient with metastatic urothelial cell carcinoma and ESRD on dialysis, safely treated with atezolizumab.
Keywords
Safe Administration , anti-PD-L1 Atezolizumab , Patient , Metastatic Urothelial Cell Carcinoma , End-Stage Renal Disease , Dialysis , ESRD
Journal title
Case Reports in Oncological Medicine
Serial Year
2019
Record number
2610616
Link To Document